Pfizer Inc. reported first-quarter financial results that surpassed Wall Street expectations, with the pharmaceutical giant posting higher-than-anticipated revenue and profit figures.

The company's strong performance was primarily attributed to increased sales of its cancer treatment portfolio, which helped drive overall revenue growth during the three-month period ending in March. The oncology segment's contribution proved significant in boosting the company's quarterly results.

In addition to newer therapeutic areas showing growth, Pfizer's established blockbuster medications also performed better than expected during the quarter. These older, proven products continued to generate substantial revenue streams for the company, contributing to the overall positive financial outcome.

Following the release of these results, Pfizer reaffirmed its financial outlook for the remainder of the year, indicating management's confidence in the company's trajectory. The pharmaceutical company maintained its previous guidance despite ongoing market uncertainties in the healthcare sector.

The better-than-expected quarterly performance comes as Pfizer continues to navigate the post-pandemic pharmaceutical landscape, balancing its traditional drug portfolio with investments in new therapeutic areas and research initiatives.